On March 19, 2018 H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using its data science and precision chemistry product engine, reported that management will present an overview of the company at the BioCentury 25th Annual Future Leaders in the Biotech Industry Conference on Friday, March 23, 2018, at 10:15 a.m. EST at the Millennium Broadway Hotel & Conference Center in New York (Press release, H3 Biomedicine, MAR 19, 2018, View Source [SID1234524968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 19, 2018 Oncoceutics, Inc. reported that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2018 annual meeting of the American Association of Cancer Research (AACR) (Free AACR Whitepaper) in Chicago, Illinois, on April 14th to April 18th (Press release, Oncoceutics, MAR 19, 2018, View Source [SID1234558371]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These abstracts highlight the unique way that ONC201 engages the dopamine receptor, leading to downstream direct anti-tumor and immune oncology effects, which are especially pronounced in tumors with dopamine pathway dysregulation. These tumors include H3 K27M mutant high grade gliomas and other cancers, where ONC201 is now in advanced clinical trials.

Additionally, the abstracts showcase the continued preclinical advancement of other members of the imipridone family. ONC212 will be featured in an oral presentation highlighting its ability to treat aggressive leukemias as a single agent, and effectively synergize with other anti-leukemic agents, specifically BCL-2 inhibitors, due to its unique GPCR target. ONC206 demonstrates parallel characteristics with ONC201, while also being differentiated by a unique binding profile.

The abstracts are listed below and categorized by topic: ONC201 clinical translation; ONC201 preclinical single agent and combinatorial activity; and analogs (ONC206 and ONC212). All poster presentations will be in McCormick Place South, Exhibit Hall A, and the oral presentation of ONC212 will take place in Room S102 – McCormick Place South (Level 1) at the times described below.

ONC201 Clinical Translation:

Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201
April 17, 2018, 8:00 AM

ONC201 induction of apoptosis in hPheo1 cell line supports use of this oral agent in ongoing phase 2 clinical trial against neuroendocrine tumors
April 17, 2018, 1:00 PM

Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients
April 18, 2018, 8:00 AM

ONC201 Preclinical Single Agent and Combinatorial Activity

Treatment and signaling contexts for the application of the imipridone ONC201 to prostate cancer cells
April 15, 2018, 1:00 PM

LB-082. ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation

April 16, 2018, 8:00 AM – 12:00 PM

Synergistic antitumor effect of ONC201 in combination with radiation therapy
April 16, 2018, 1:00 PM

Combination ONC201 and radiation therapy in the treatment of breast cancer
April 16, 2018, 1:00 PM

Analogs (ONC206 and ONC212):

Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206
April 17, 2018, 1:00 PM

The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132
April 17, 2018, 3:35 PM – Oral Presentation

On March 19, 2018 Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, reported the appointment of Dr. Leila Alland to the position of Chief Medical Officer (CMO), effective March 26, 2018 (Press release, , 19 19, 2018, View Source [SID1234524894]). As CMO, Dr. Alland will be responsible for the clinical strategy and execution of Affimed’s first-in-class NK and T cell engager programs through early and late stage clinical trials. Dr. Alland brings to the Company over 20 years of experience in industry and academic research with a strong track record of successful oncology and hematology drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am pleased to announce the appointment of Dr. Alland as our new Chief Medical Officer as she brings with her a wealth of expertise in immuno-oncology drug development including PD-1- and EGFR-targeting agents," said Dr. Adi Hoess, CEO of Affimed. "With Dr. Alland leading our strategy and execution in the clinic, we look forward to advancing our robust pipeline of both mono- and combination therapeutics through clinical development to regulatory approval."

Dr. Alland has broad experience as a clinical leader developing both large and small molecule oncology products for solid and hematological malignancies, including Opdivo, Tagrisso, and Tasigna. Dr. Alland most recently served as CMO of Tarveda Therapeutics, developing clinical candidates for solid tumors. Prior to that, she was Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she led Phase 1 and Phase 2 clinical development of oncology and immuno-oncology programs including a Phase 2 registration study that contributed to the accelerated approval of Tagrisso. Previously, Dr. Alland served at Bristol-Myers Squibb as clinical head for multiple early phase oncology programs including immuno-oncology antibody therapeutics, and at Novartis where she led the clinical development program for Tasigna. Dr. Alland is also an experienced pediatric hematologist/oncologist and accomplished scientist, having served on the faculty at Albert Einstein College of Medicine, New York City, where she was awarded the prestigious James S. McDonnell Foundation Scholar Award for research.

"Affimed’s novel tetravalent bispecific antibodies for immune cell engagement offer a unique approach to accelerate the trajectory of the immuno-oncology field and achieve significant benefit for patients," said Dr. Leila Alland. "I am excited to be joining the accomplished team at Affimed and look forward to advancing the differentiated pipeline of NK and T cell engagers for patients with Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia and other malignancies."

Dr. Alland completed her fellowship in pediatric hematology and oncology at Memorial Sloan Kettering Cancer Center, NY and her internship and residency at The Children’s Hospital of Philadelphia, PA. She received her B.A. from the University of Pennsylvania and her M.D. from New York University School of Medicine.

On March 19, 2018 Synlogic, Inc., (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, reported that preclinical data from its immuno-oncology (IO) program will be presented at the upcoming annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) being held April 14 to 16, 2018, in Chicago (Press release, Synlogic, MAR 19, 2018, View Source [SID1234524892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two poster presentations featured at AACR (Free AACR Whitepaper) highlight the application of Synthetic Biotic medicines for the potential treatment of a variety of solid tumors. Abstracts can be found at www.aacr.org

Activation of Innate and Adaptive Immunity via Combinatorial Immunotherapy using Synthetic Biotic Medicines
Abstract Number: LB-131
Session Title:Late-Breaking Research: Immunology 1
Date/Time:Monday, April 16, 2018; 8:00 a.m. – 12:00 p.m. Central Time

Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic Medicines
Abstract Number: 2920
Session Category: Experimental and Molecular Therapeutics
Session Title: New Targets 2
Date/Time:Monday, April 16, 2018; 1:00 p.m. – 5:00 p.m. Central Time
Session Location:McCormick Place South, Exhibit Hall A, Poster Section 40

On March 19, 2018 Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, reported that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 17th Annual Healthcare Conference on, March 28, 2018 at 11:00 AM EDT at the Westin Grand Central Hotel in New York, NY (Press release, , 19 19, 2018, View Source;p=irol-news&nyo=0 [SID1234524896]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live audio webcast of the presentations on the "Investor Relations" page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.